The patented Parsortix PC1 system is the first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis.
Featured Ngaio News Articles
Innovative HER2 CTC Assay in Development
Enhance longitudinal monitoring in breast cancer, predict therapeutic responses, and optimise subject selection for clinical trials with ANGLE’s advanced HER2…